Overview

Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the effect of renal impairment on the pharmacokinetics (PK) of teduglutide following subcutaneous (SC) administration of 10 mg teduglutide. Secondary objectives are to assess the safety and tolerability of 10 mg teduglutide. A further objective is the description of the PK of teduglutide following SC administration of 10 mg teduglutide in elderly (≥ 65 years) healthy subjects compared to non elderly healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Nycomed

Collaborator:

NPS Pharma

Treatments:

Teduglutide